Scar management: prevention and treatment strategies

Chen, Margaret A; Davidson, Terence M.

doi:10.1097/01.moo.0000170525.74264.f8

Cited by 141 publications

(97 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inhibitory SMAD 7 prevents phosphorylation of R-SMADs by forming stable associations with activated type I TGF-β receptors and thus provides negative feedback to the actions of TGF-β (56). Indeed, a potential therapeutic benefit of SMAD 7 overexpression has already been shown in bleomycin-induced lung fibrosis, postobstructive renal fibrosis and excessive cutaneous scar formation (57)(58)(59). SMAD 3 inhibition and SMAD 7 overexpression may thus be potential therapeutic targets to improve excessive scarring.…”

Section: Fibrogenic Responsementioning

confidence: 99%

“…5-FU is a pyrimidine analog that is used as an antimetabolite in cancer chemotherapy (109). 5-FU is converted intracellularly to its active version, which was suggested to directly increase fibroblast apoptosis via inhibiting DNA synthesis preferentially in rapidly proliferating and metabolizing cells (58,139). In 1999, Fitzpatrick (140) was the first to report the use of 5-FU to effectively reduce scars during his 9-year experience, in which he administered more than 5000 injections to more than 1000 patients.…”

Section: Current Treatment Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Gauglitz

Körting

Pavicic

et al. 2010

Mol Med

1,178

1,012

View full text Add to dashboard Cite

Excessive scars form as a result of aberrations of physiologic wound healing and may arise following any insult to the deep dermis. By causing pain, pruritus and contractures, excessive scarring significantly affects the patient's quality of life, both physically and psychologically. Multiple studies on hypertrophic scar and keloid formation have been conducted for decades and have led to a plethora of therapeutic strategies to prevent or attenuate excessive scar formation. However, most therapeutic approaches remain clinically unsatisfactory, most likely owing to poor understanding of the complex mechanisms underlying the processes of scarring and wound contraction. In this review we summarize the current understanding of the pathophysiology underlying keloid and hypertrophic scar formation and discuss established treatments and novel therapeutic strategies.

show abstract

Section: Fibrogenic Responsementioning

confidence: 99%

Section: Current Treatment Strategiesmentioning

confidence: 99%

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Gauglitz

Körting

Pavicic

et al. 2010

Mol Med

1,178

1,012

View full text Add to dashboard Cite

show abstract

“…In general, TGF-β1 and TGF-β2 physiologically promote fibroblast proliferation and collagen production in the proliferative phase of normal wound healing and have been found to be overproduced and unregulated in keloidal tissue. 112 In contrast, TGF-β3 appears to function as a scar inhibitor. 113 Animal studies have demonstrated promising results with topical application of TGF-β1 and TGF-β2 antagonists resulting in expedited reepithelialization and reduced scar formation and wound contraction in partial-thickness/full-thickness porcine burns as well as in rabbit skin excision models.…”

Section: Transforming Growth Factor-βmentioning

confidence: 99%

Scar Management in the Pediatric and Adolescent Populations

Krakowski

Totri

Donelan³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

For most children and adolescents who have developed symptomatic scars, cosmetic concerns are only a portion of the motivation that drives them and their caregivers to obtain treatment. In addition to the potential for cosmetic disfigurement, scars may be associated with a number of physical comorbidities including hypertrichosis, dyshidrosis, tenderness/pain, pruritus, dysesthesias, and functional impairments such as contractures, all of which may be compounded by psychosocial factors. Although a plethora of options for treating scars exists, specific management guidelines for the pediatric and adolescent populations do not, and evidence must be extrapolated from adult studies. New modalities such as the scar team approach, autologous fat transfer, and ablative fractional laser resurfacing suggest a promising future for children who suffer symptomatically from their scars. In this state-of-the-art review, we summarize cutting-edge scar treatment strategies as they relate to the pediatric and adolescent populations.

show abstract

“…Yara iyileşmesi oldukça karışık ve mükemmel bir dengede ilerleyen fizyolojik olaylar dizisidir. Yara iyileşmesi sürecinde inflamasyon, proliferasyon ve maturasyon evreleri birbirini takip eder 11 . Granülasyon fazında makrofajlarda sitokin sentezler bunun sonucunda reepitelizasyon, kan dolaşımının düzenlenmesi ve yaralı dokunun güçlenmesi sağlanır 13 .…”

Section: Discussionunclassified

“…Bu nedenle cerrahi insizyon lokalizasyonunun seçiminde bu tip kaygılar önemli rol oynamıştır. Patolojik skar gelişimi görünümü itibariyle psikososyal etkileri olduğu kadar ağrı, kaşıntı ve gerginlik oluşturarak da yaşamı olumsuz etkileyebilmektedir 11 . Ancak genç yaş grubunda tek tip bir cerrahi insizyon sonrası oluşabilecek skar oluşumunu ve skar tipini etkileyebilecek olası risk faktörleri üzerine literatürde yeterli veri yoktur.…”

Section: Introductionunclassified

Risk factors for scar formation after surgical incision

Kelekci¹,

Karaca²,

Demirel³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

Background and Design:The risk factors for scar development are still being discussed by dermatologists and surgeons. The aim of this study was to analyze the independent risk factors for the development of incisional scar type which develop after an abdominal delivery. Materials and Methods: Four hundred-ninety-two women who underwent caesarean operation one year ago or earlier were included in this study. After a detailed anamnesis and physical examination, data including demographic features, type of suture materials, time of suture removal, presence of striae, family history of hypertrophic scar, history of infection and/or hematoma, and total weight gain during pregnancy were recorded from the medical reports of patients. The scars were separated into two groups as atrophic and hypertrophic. The obtained data were compared according to the type of scars. A p value of less than 0.05 was considered statistically significant. Results: Both groups were similar in terms of demographic data. Atrophic scars were found in 408 of 492 patients and hypertrophic scars in 84 patients. Presence of wound site infection or hematoma (odds ratio OR: 5.64, 95%, confidence interval CI: 3.12-10.22), presence of striae (OR: 1.80, 95% CI: 1.12-2.91) and positive family history of hypertrophic scar (OR: 4.25 95% CI: 2.60-6.94) were associated with hypertrophic

show abstract

Scar management: prevention and treatment strategies

Cited by 141 publications

References 45 publications

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Scar Management in the Pediatric and Adolescent Populations

Risk factors for scar formation after surgical incision

Contact Info

Product

Resources

About